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ABSTRACT  
Multiple drug resistance (MDR) is the ability of some 
microorganisms to resist the actions of multiple antimicrobial 
agents. MDR include those resistant to multiple antibacterial, 
antifungal, antiviral, and anti-parasitic drugs. Similar activities of 
some microorganisms to certain chemical (drug) that would 
normally kill them or limit their growth is called 
antimicrobial resistance (AMR). Multi drug resistance can be 
classified as primary resistance, secondary resistance, intrinsic 
resistance, extensive resistance and clinical resistance. The 
classes of antibiotics that fall victim of resistance include beta-
lactams, glycopeptide, aminoglycosides, sulphonamides, 
cephalosporins etc. The mode of action of antimicrobial drug 
includes cell wall synthesis inhibitors, protein synthesis inhibitor, 
blockage of key metabolic pathways, nucleic acid synthesis 
inhibitors etc. Bacteria often become resistant and this could be 
through one of several biochemical mechanisms such as 
mutation, destruction or inactivation and efflux or genetic transfer 
of materials between bacteria by several means such as 
conjugation, transformation and transduction. The mode of action 
of MDR protozoa occurs through decrease of drug uptake, the 
export of drugs from the parasite by P-glycoproteins and other 
traffic ATPases etc. The mode of action of MDR helminths occurs 
through genetic changes in the drug target, changes in drug 
transport, drug metabolism etc. The mode of action of antiviral 
drugs usually target viral DNA polymerase having the reverse 
transcriptase activity to inhibit the viral replication. The mode of 
action of MDR fungi occurs as they have learnt to modify the 
antifungal drug targets or most commonly increase the efflux of 
the incoming drugs There are various ways to reverse this 
resistance such as washing hands after seeing each patient, the 
public should wash raw fruit and vegetables thoroughly to clear off 
both resistant bacteria and possible antibiotic residues, avoid the 
misuse of antibiotics, etc.  
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INTRODUCTION 
Multiple drug resistance (MDR) is an antimicrobial resistance 
exhibited by some microorganisms to multiple antimicrobial drugs. 
MDR microorganisms are mostly threatening to public health 
because they resist multiple antibiotics. Other MDR include those 
that are resistant to multiple antifungal, antiviral, and anti-parasitic 
drugs (Magiorakos, 2014; WHO, 2018). 
 
A broad range of biochemical and physiological mechanism may 
be culpable for resistance (Liu and Pop, 2009; WHO, 2014). In 
the specific case of antimicrobial agents, the complexity of the 
processes that contribute to emergence and propagation of 
resistance cannot be overestimated, and due to the lack of 
elemental knowledge on these topics is one of the major reasons 
that there has been so limited significant fulfillment in the effective 
prevention and control of resistance development (Liu and Pop, 
2009; WHO, 2014). 
There are specific classes of compounds of antimicrobial that are 
capable of destroying or inhibiting microorganisms even in high 
dilutions. (Laxminarayan et al., 2013). Antibiotics are substances 
that are produced by the natural metabolic processes of some 
microorganisms which can either inhibit or destroy other 
microorganisms (Talaro and Talaro, 2002; Nester et al., 2004). 
The current root of antimicrobial drugs is diverse (Rudramurthy, 
2016). The Synthetic antimicrobial drugs in the laboratory are 
derived from dyes or other organic compounds through chemical 
reactions (Laxminarayan et al., 2013). For more than 60 years, 
antibiotics have been critical in the fight against infectious 
diseases which are caused by bacteria and other microorganism 
(Laxminarayan and Heymann, 2012). Nevertheless disease-
causing microbes that have come to be resistant to antibiotic drug 
treatment such as pneumonia, septicemia, gonorrhea, 
tuberculosis, wound infections, and diseases that have become 
difficult to treat with antibiotics remains an increasing public health 
problem (WHO, 2013). One side of the issue is that bacteria and 
other microbes that cause infections are exceptionally volatile and 
have developed various ways to resist antibiotics and other form 
of antimicrobial drug (Boucher et al., 2013). Another side of the 
issue is as a result of increasing use and misuse of current 
antibiotics in human, veterinary medicine and in agriculture 
(Todar, 2012). Microbes developing resistance, as well as due to 
economic reasons have arisen in the research and development 
in the search for novel antibiotics in order to provide a wide range 
of effective drugs at all times (WHO, 2014). 
 
 Antimicrobial Resistance  
This is the ability of microbes to grow in the presence of a 
chemical (drug) that would normally restrict their growth or 
destroy them (Huttner et al., 2013).Microorganisms resistance to 
antimicrobial drug was basically effective for the treatment of 
infection caused by those microorganisms. Drug resistant 
microorganisms include (bacteria, fungi, viruses and parasite). 
These microorganisms are able to combat attack by antimicrobial 
drugs so that basic treatment becomes ineffective and infection 
prevails, raising the risk of spreading to others (Roca et al., 2015). 
Antimicrobial resistance makes it harder to eradicate infections 
from the body as current drugs become less effective. 
Consequently, some infection diseases today are more difficult to 
treat than they were just a few decades ago (NIAID, 2009). As 
more microorganisms became resistant to antimicrobials, the 
protective value of these drugs is reduced due to the use and 
misuse of antimicrobial drugs and this is among the factors that 
have contributed to the development of drug resistant microbes 
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Mycobacterium tuberculosis (TB), Methicillin-resistant 
Staphylococcus aureus (MRSA), Vacomycin- resistant 
Enterococci (VRE), and Multidrug- resistant Neisseria 
gonorrhoeae (Gonorrhea), Gram- negative bacteria (NIAID, 2009; 
Arumugam, 2016; Swamy and Sinniah, 2016). 
 
Classification of Multi Drug Resistance 
Administration of appropriate doses of drugs for a particular 
duration of time, survival of different microbial strains suggests 
the high levels of resistance developed in them (Tanwar et al., 
2014). This clinical failure is as a result of not only the 
antimicrobial resistance but also the suppressed immune function, 
deprived or poor drug bioavailability, or increased rate of drug 
metabolism. Multi drug resistance can be classified as primary or 
secondary resistance (Tanwar et al., 2014). 
 
Primary resistance: occurs when the organism has never 
confronted the drug of interest in a particular host i.e. it is a drug 
resistance in patient who has not received any previous anti-
tubercular treatment (Mathur, et al., 2000; Paramasivan et al., 
2000 Hemvani et al., 2001). For example primary drug resistance 
tuberculosis, this occurs in patients who have not previously 
received tuberculosis treatment. Primary drug resistance is known 
to be caused by the dissemination of drug-resistant strains 
(Jassal and Bishai, 2009). 
 
Secondary resistance: This is also known as “acquired 
resistance,” this term is used to define the resistance that only 
occurs in an organism after an exposure to the drug (Loeffler and 
Stevens, 2003; Khalilzadeh et al., 2006). This can also be define 
as resistance that evolve in a patient who has previously received 
chemotherapy (Mathur, et al., 2000; Paramasivan et al., 2000; 
Hemvani et al., 2001). For example acquired drug resistance 
expressed tuberculosis isolated from patients who currently are 
getting or until that time have received anti-tuberculosis drug 
treatment for at least one month (Van Rie, et al., 2000). 
 
It can further be classified as follows; 
 
Intrinsic resistance: Intrinsic resistance is the innate ability of a 
microorganism to resist activity of a particular antimicrobial agent 
through its inherent structural or functional characteristics, which 
allow tolerance of a particular drug or antimicrobial class 
(Chuanchuen et al., 2003). This can also be called “insensitivity” 
since it occurs in organisms that have never been susceptible to 
that particular drug (Alekshun and Levy, 2007). Such natural 
insensitivity can be due to:   
 Lack of affinity of the drug for the bacterial target   
 Inaccessibility of the drug into the bacterial cell    
 Extrusion of the drug by chromosomally encoded 
active exporters   
 Innate production of enzymes that inactivate the drug   
(Alekshun and Levy, 2007). 
For example, Gram-positive bacteria to aztreonam (a beta-
lactam), Gram-negative bacteria to vancomycin, anaerobic 
bacteria to aminoglycosides, aerobic bacteria to metronidazole 
etc (Forbes and Sahm, 1998; Giguere et al., 2006). 
 
Extensive resistance: 
It defines the ability of organisms to withstand the inhibitory 
effects of at least one or two most effective antimicrobial drugs 
(Loeffler and Stevens, 2003). Also termed as XDR, this seemed 
to arise in patients after they have undergone a treatment with 
first line drugs, for example, XDR-TB (extensive drug resistant 
tuberculosis) resistance against fluoroquinolone (Gandhi et al., 
2003; Loeffler and Stevens, 2003). 
 
Clinical resistance: Clinical resistance is described by the 
situation in which the infecting organism is inhibited by a 
concentration of an antimicrobial agent that is linked with a high 
likelihood of therapeutic failure or reappearance of infections 
within an organism as a result of impaired host immune function 
especially the pathogen is inhibited by an antimicrobial 
concentration that is higher than could be carefully attained with 
normal dosing (Loeffler and Stevens, 2003) 
 
Common Drugs: Victim of Resistance 
 
Table 1: Microorganisms and their resistance mechanism to 
various antibiotics 
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Multidrug Resistance Bacteria and Mode of Action 
Multi drug resistance (MDR) bacteria are bacteria that have 
become resistant to certain commonly used antibiotics. There are 
many different types of MDR bacteria that can easily be found 
throughout the environment including water and soil (Vaz-Moreira 
et al., 2014). They cause the same type of infections as non-
resistant bacteria (Tanwar et al., 2014). The difference is that 
when an infection with multi-drug resistant bacteria is developed, 
the choice of suitable antibiotic to treat the infection may be 
considerably more limited, example include Psuedomonas 
aeroginosa, Staphylococcus aureus (MRSA), Esherichia coli, 
Acinetobacter baumannii, Klebsiella pneumoniae, Mycobacterium 
tuberculosis, Neisseria gonorrhoeae e.tc. (Arias and Murray, 
2009; NHS, 2017). Antibiotic resistance could occur in bacteria 
through four types of mechanisms:  
 
Drug inactivation or modification: for example, enzymatic 
deactivation as in penicillin G in some penicillin-resistant bacteria 
through the production of β-lactamases (Jacoby and Munoz-Price, 
2005). Protecting enzymes manufactured by the bacterial cell will 
add an acetyl or phosphate group to a specific site on the 
antibiotic, which will diminish its capacity to bind to the bacterial 
ribosomes and disrupt protein synthesis (Giedraitien˙e et al., 
2011; Jose and Cesar, 2016).  
 
Modification of target- or binding site: for example, alteration 
of PBP-the binding target site of penicillin's-in MRSA and other 
penicillin-resistant bacteria, or modification in structure of 
ribosomal protection proteins (Tang et al., 2014). These proteins 
guard the bacterial cell from antibiotics through changes its 
conformational shape. Change of proteins conformational shape 
allows these proteins to loss their activity so, prevent inhibit 
protein synthesis, and this help in grow of bacteria and spread it 
(Jose and Cesar, 2016). 
 
Alteration of metabolic pathway: for example, absence of 
paraaminobenzoic acid (PABA), this is precursor for the synthesis 
of folic acid and nucleic acids (Jose and Cesar, 2016). 
 
Reduced drug accumulation: By decreasing drug permeability 
or increasing active pumping out of drugs through cell membrane 
(Jose and Cesar, 2016). The balance of antibiotic uptake and 
elimination determines the susceptibility of bacteria to a particular 
drug. Thus, reducing the amount of antibiotic able to pass through 
the bacterial cell membrane is one strategy used by bacteria to 




Multidrug Resistance Protozoa and Mode of Action 
Parasitic protozoa are responsible for some of the most 
devastating and prevalent diseases of humans and domestic 
animals. Even though protozoa are eukaryotes and usually 
contain many of the organelles and metabolic pathways of their 
hosts, the differences in biochemistry between parasite and host 
are great enough to leave a large window for the development of 
parasite-specific drugs (Brianti et al., 2016). For example Malaria 
(Plasmodium sp.), the various forms of (muco) cutaneous and 
visceral leishmaniasis (Leishmania sp.), African sleeping sickness 
(Trypanosoma brucei gambiense, T'ypanosoma brucei 
rhodesiense), Toxoplasma gondii etc (Doliwa et al., 2013; Oliva et 
al., 2014). Drug resistance mechanisms here in certain 
protozoans could be described as follows: 
Decrease of drug uptake because of the loss of a transporter 
required for uptake. This decrease contributes to resistance to 
arsenicals and diamidines in African trypanosomes (Borst and 
Ouellette, 1995; Upcroft and Upcroft, 2001). 
 The export of drugs from the parasite by P-glycoproteins and 
other traffic ATPases. This export could potentially be an 
important mechanism of resistance, as these proteins are richly 
represented in the few protozoa. There are indications that such 
transmembrane transporters can be involved in resistance to 
emetine in Entamoeba sp., to mefloquine in Plasmodium sp., and 
to antimonials in Leishmania sp (Borst and Ouellette, 1995; 
Upcroft and Upcroft, 2001). 
The involvement of the PgpA P-glycoprotein of Leishmania sp. in 
low level resistance to arsenite and antimonials. This raise the 
possibility that this protein transports glutathione conjugates of 
arsenite and antimonials rather than the compounds themselves 
(Borst and Ouellette, 1995; Upcroft and Upcroft, 2001). 
Loss of drug activation as the main mechanism of metronidazole 
resistance in Trichomonas and Giardia sp. Recent evidence 
indicates that a decrease of the proximal cellular electron donor 
for metronidazole activation, ferredoxin, is the main cause of 
resistance in Trichomonas (Borst and Ouellette, 1995; Upcroft 
and Upcroft, 2001). 
Resistance arising through alteration of drug targets. The amino 
acid substitutions in the dihydrofolate reductase-thymidylate 
synthase of Plasmodium sp. are good examples of this 
mechanism (Borst and Ouellette, 1995; Upcroft and Upcroft, 
2001). 
 
Multidrug Resistance Helminths and Mode of Action 
Helminths are a diverse group of parasitic worms, encompassing 
nematodes, cestodes and trematodes are a major health problem 
for human and animals in many part of the world (Kaplan, 2004; 
Hotez et al., 2008). 
 
Genetic changes in the drug target 
Most efforts to identify drug resistance in helminths have 
concentrated on alteration of the drug’s cellular target, identified 
by changes in the genome sequence. Several single-nucleotide 
polymorphisms (SNPs) have been associated with resistance 
(Gilleard, 2006). SNPs are unique genetic differences between 
individuals and are the basis of genetic differences in a 
population. SNPs can also arise by gene mutation after drug 
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Changes in drug transport 
Although genetic selection contributes to anthelmintic resistance, 
other mechanisms also contribute. Early studies in cancer cells 
showed that some tissues were inherently resistant to treatment, 
whereas other tumours acquired resistance after treatment (Zhou, 
2008).This resistance was to a variety of drugs and was mediated 
by the expression of a membrane protein known as P-
glycoprotein (Zhou, 2008). The transport of several anthelmintics 
(including ivermectin, benzimidazoles and imidazothiazole 
derivatives) by human P-glycoprotein in cells expressing the 
transport protein has been reported (Nare et al., 1994; Brayden 
and Griffin, 2008).  This suggests that drug efflux mechanisms 
might function in drug resistance in Helminths that contain 
functionally related transport proteins. 
 
Drug metabolism 
There is also evidence for increased drug metabolism as a 
mechanism for drug resistance in parasites, but this is mainly 
substantiated for protozoa. However, many anthelmintics 
currently in use cause increased free radical production as part of 
their cytotoxic activity – for example, praziquantel and artemisinin 
used to treat Schistosoma sp (El-Bassiouni et al., 2007). 
 
Multidrug Resistance Viruses and Mode of Action 
Viruses have developed numerous resistance mechanisms that 
enable them to evade the effect of antimicrobials and antivirals. 
As a result, many have become resistant to almost every 
available means of treatment (McKeegan et al., 2002).This 
problem, although not new, is becoming increasingly acute and it 
is now clear that a fundamental understanding of the mechanisms 
that microbes and viruses deploy in the development of 
resistance is essential if we are to gain new insights into ways to 
combat this problem (McKeegan et al., 2002). Antiviral drugs 
usually target viral DNA polymerase having the reverse 
transcriptase activity to inhibit the viral replication. Drug resistant 
mutant strains undergo mutations in the reverse transcriptase 
domains of the polymerase gene which affects the interaction 
between the drug and the enzyme. Resistance to the inhibitory 
effects of drug on the enzyme can also emerge due to any 
conformational changes or altered binding of substrate to the viral 
polymerase (Strasfeld and Chou, 2010). 
 
Multidrug Resistance Fungi and Mode of Action 
Fungal cells have developed several strategies to deal with the 
antifungal. They have learnt to modify the antifungal drug targets 
or most commonly increase the efflux of the incoming drugs. Cell 
wall, in fungi plays a crucial role in their survival. Drugs affecting 
ergosterol synthesis (e.g polyenes) in fungi, thus, blocking the cell 
to grow then (He et al., 2013). Such as reduction in the ergosterol 
content in fungal plasma membrane) resulting in decreased 
permeability and uptake of drugs into the cell (Loeffler and 
Stevens, 2003; Singh, 2013). Altered membrane composition 
(such as 𝛽-1, 3-glucan and lipid content in fungal cell membrane) 
also leads to lack of active target sites for the drugs (e.g., 
echinocandins in fungi to bind (He et al., 2013). Mutations in the 
genes encoding for the target cause modifications at the 
molecular level and retain cellular function by reducing 
susceptibility to inhibition (Loeffler and Stevens, 2003; Singh, 
2013). Another mechanism of MDR was found to be an over 
expression of drug target enzymes leading to target by pass due 
to modification in certain metabolic pathways (e.g., azoles and 
allylamines in fungi), which causes production of alternate target 
molecules and interference in some protein synthesis (He et al., 
2013). Examples include yeast such as Candida species can 
become resistant under long time treatment with azoles 
preparations requiring treatment with a different drug class. 
Scedosporium proflificans infections are almost uniformly fatal 
because of their resistance to multiple antifungal agents (Howden 
et al., 2003). 
 
Mechanisms and the Emergence of Antibiotic Resistance  
The long awaited “superbug” arrived in the summer of 2002 
Staphylococcus aureus, a common but sometimes deadly 
bacterium, had acquired a new antibiotic resistance gene. This 
new strain was isolated from foot ulcers as diabetic patients in 
Detroit, Michigan, methicillin resistant (formally methicillin-
resistant) S. aureus (MRSA) had been well known as the bane of 
hospitals (Deurenberg et al., 2007; Willey et al., 2008; Paterson et 
al., 2014). The newer strain had developed resistance to 
vancomycin, one of the few antibiotics that were still able to 
control S. aureus. This new vancomycin resistant S. aureus 
(VRSA) strain also resisted most other antibiotics including 
ciprofloxacin, methicillan and penicillin. Isolated from the same 
patient was dread of hospitals vancomycin-resistant Enterococci 
(VRE) (CDC, 2004). Genetics analysis reveal that the patient’s 
own vancomycin sensitive S. aureus had acquired the 
vancomycin resistance gene VanA, from VRE through 
conjugation, so was born a new threat to the health of the human 




Fig. 2: Biochemical and genetic aspects of antibiotic resistance 
mechanisms in bacteria (Dzidic et al., 2008). 
 
Bacteria often become resistant in several ways. Unfortunately, a 
particular type of resistance mechanism is not confined to a single 
class of drugs. Two bacteria may use different resistant 
mechanisms to withstand the same chemotherapeutic agent 
(Willey et al., 2008).  
Susceptible bacteria can acquire resistance to antimicrobials by 
either genetic mutation or by accepting antimicrobial resistant 
genes from other bacteria (Martinez et al., 2009). This could be 
through one of several biochemical mechanisms such as 
mutation, destruction or inactivation, efflux or genetic transfer of 
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materials between bacteria by several means such as 
conjugation, transformation and transduction (Wiley et al., 2008; 
Munita and Arias, 2016). 
 
Mutation 
This is a change in the DNA that can sometimes cause a change 
in the gene product, which is the target of the antimicrobial. When 
a susceptible bacterium comes in contact with a therapeutic 
concentration of antimicrobials, like fluroquinolones, the 
antimicrobial can bind to the specific enzymes, in this case, DNA 
gyrase (Cattoir et al., 2007). The DNA gyrase is an essential 
bacterial enzyme required for DNA replication. The end result is 
that fluroquninolones blocks bacterial DNA replication leading to 
cell death (FDA, 2004; Cattoir et al., 2007). However, when 
spontaneous mutations occur in specific areas of the genes 
encoding these enzymes, antimicrobials no longer bind efficiently. 
This allows the bacterium to continue DNA replication. Pathogens 
often become resistant simply by preventing entrance of the drug. 
Many gram negative bacteria are unaffected by penicillin G 
because it cannot penetrate the envelops outer membrane 
(Delcour, 2009). Genetic mutations that lead to changes in 
penicillin binding proteins also render a cell resistant. A decrease 
in permeability can lead to sulfonamide resistance (FDA, 2004). 
 
Destruction or Inactivation  
Many bacteria possess genes which produce enzymes that 
chemically degrade or deactivate the antimicrobial rendering them 
ineffective against bacterium. Here the antimicrobial is either 
degraded or modified by enzymatic activity before it can reach the 
target site and damage the bacterial cell (Bush, 2013).The best 
known example is the hydrolysis of the β - lactam ring of 
penicillin’s by the enzymes penicillinase drugs are also inactive by 
the addition of chemical group (FDA, 2004). For example, 
chioramphenicol contains two hydroxyl groups that can be 
acetylated in a reaction catalyzed by the enzyme chioramphenicol 
acyltransferase with actyl CoA as the donor. Aminoglycosides can 
be modified and inactivated in several ways. Acetyltransferases 
catalyze the acetylation of amino groups. Some aminoglycoside 
modifying enzymes catalyze the addition of hydroxyl groups of 
either phosphates (phosphotransferasses) or adenyl groups 
(addenyltransferases) (FDA, 2004; Bush, 2013). 
 
Efflux  
One of the most common drug resistance mechanisms is active 
efflux of drugs from, the inside of the bacterial cells. Such drug 
resistant bacteria habour energy-driven drug efflux pumps which 
extrude antimicrobial agents thus reducing their intracellular 
concentration to sub or non-inhibitory levels (Piddock, 2006). 
Efflux pump is essentially a channel that actively exports 
antimicrobial and other compounds out of the cell. The 
antimicrobial enters the bacterium through a channel termed as 
porin and then is pumped back out of the bacterium by the efflux 
pump (FDA, 2004). Because they are relatively non-specific and 
can pump many different drugs, these transport proteins often are 
called multidrug resistant pumps. There are two main types of 
active efflux pumps; the first type called primary active transport 
uses the hydrolysis of ATP to actively efflux drugs from cells, 
while the second type, called secondary active transport, uses an 
iron gradient for actively efflux drugs from cells (Poole, 2005).The 
ATP driven transporters are also known as ABC (for ATP Binding 
Cassette) or P-glycoprotein transporters. Both active transport 
systems are used by bacteria to resistant the inhibitory effects of 
antimicrobial agents and are often referred to as efflux pumps 
(Sanath and Manuel, 2013). Many are drug/proton antiporters that 
are proton enters the cell that the drug leaves. Such systems are 
present in E. coil, P. aeruginosa and S. aureus etc (Willey et al., 
2008). 
 
Fig 3: Showing Efflux and Enzymatic degradation (Todar, 2012). 
 
Measures to Reverse Resistance 
In main genetic processes, horizontal gene transfers, the resistant 
microbe is affected not only in its ability to withstand the antibiotic, 
but due to the fact that its interaction with the host and its ability to 
be transmitted between hosts. Usually, it is observed that most 
resistance mechanisms will confer a reduction in bacterial fitness, 
which might be expressed as reduced growth and survival inside 
and outside a host, and reduced virulence or transmission rate 
from environment to host or between hosts (Todar, 2002; 
Laxminarayan, 2003; Dromigny and Perrier-Gros-Claude, 2003).  
Washing hands after seeing each patient is a major and obvious, 
but too often overlooked precaution (Okeke et al., 2001). Two 
epidemiological studies, of erythromycin resistance in 
Streptococcus pyogenes and penicillin resistance in 
Streptococcus pneumonia, have been suggested as providing 
support for their versatility of resistance in community settings 
(Masters et al., 2003; Szczepannowski et al., 2009).  
Several laboratory and epidemiological studies indicate that 
various processes are predicted to cause long-term persistence of 
resistant bacteria. One process is compensatory evolution, where 
the costs of resistance are ameliorated by additional genetic 
changes, resulting in the stabilization of resistant bacteria in the 
population. Even though most resistance is associated with 
fitness cost, some resistance mutations appear to be gratuitous. 
The occurrence of such cost-free resistances will also cause 
irreversibility since the driving force for reversibility is absent 
(Woodhead and Blasi, 2005). 
The public should wash raw fruit and vegetables thoroughly to 
clear off both resistant bacteria and possible antibiotic residues. 
When they receive prescriptions for antibiotics, they should 
complete the full course of therapy (to ensure that all the 
pathogenic bacteria die) and should not "save" any pills for later 
use (Stephen and Kennedy, 2011). 
 Consumers also should refrain from demanding antibiotics for 
colds and other viral infections and might consider seeking non 
antibiotic therapies for minor conditions, such as certain cases of 
acne. They can continue to put antibiotic ointments on small cuts, 
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but they should think twice about routinely using hand lotions and 
a proliferation of other products now imbued with antibacterial 
agents. New laboratory findings indicate that certain of the 
bacteria-fighting chemicals being incorporated into consumer 
products can select for bacteria resistant both to the antibacterial 




Inadequacy of available antimicrobial drugs compels continuous 
development of newer drugs. MDR is an unavoidable natural 
phenomenon, posing a serious worldwide menace to public 
health. A cooperative action at global level is a must to combat 
the MDR. Pathogens tend to adopt various resistance 
mechanisms to survive the unfavourable conditions. Improved 
knowledge of molecular mechanisms controlling MDR should 
facilitate the development of novel therapies to combat these 
intransigent infections and will help cultivate a deeper 
understanding of the pathobiology of microbial organisms. 
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